Welcome to our dedicated page for Scisparc news (Ticker: SPRC), a resource for investors and traders seeking the latest updates and insights on Scisparc stock.
Comprehensive Overview of SciSparc Ltd (SPRC)
SciSparc Ltd is a specialty clinical‐stage pharmaceutical company that leverages cutting‐edge cannabinoid technologies to develop innovative immunotherapy products and address central nervous system disorders. At its core, SciSparc focuses on the development of therapies derived from cannabinoid molecules, incorporating advanced biotechnology, immunotherapy, and clinical research methodologies. This dual‐focused enterprise operates across two distinct segments: one dedicated to clinical drug development and regulatory pathways, and another which drives the online sale of hemp-based consumable products.
Clinical-Stage Drug Development
The company’s primary business revolves around its clinical-stage drug development programs. SciSparc employs a portfolio based on both THC and non-psychoactive CBD compounds to create novel treatments for disorders such as Tourette Syndrome, Alzheimer’s disease with agitation, autism spectrum disorder, and status epilepticus. Utilizing a rigorous, research-driven approach, the company undertakes controlled clinical trials designed to evaluate drug efficacy, safety, and tolerability. With its IND applications and approvals for advanced clinical programs, SciSparc demonstrates its commitment to meeting stringent regulatory standards and addressing unmet medical needs in its target therapeutic areas.
Innovative Technology and Intellectual Property
SciSparc’s market positioning is strengthened by its robust portfolio of patents and proprietary technologies. The company’s innovations in cannabinoid pharmaceuticals are not only geared towards improving treatment outcomes but also distinguishing its offerings from traditional therapies. By investing in advanced research platforms, including computational drug discovery and predictive artificial intelligence models, SciSparc is able to screen and identify promising molecular candidates for further development. This technological prowess, combined with a clear focus on regulatory compliance and scientific excellence, forms the backbone of its strategic differentiation.
Online Sales and Hemp-Based Consumer Products
In addition to its core clinical operations, SciSparc diversifies its business model through a reportable segment that manages the online sale of a wide range of hemp-derived products. These products, which include hemp gummies, oil capsules, topical gels, creams for beauty and hair treatments, and other nutraceutical items, are manufactured domestically in the United States. This segment not only leverages SciSparc’s expertise in cannabinoid science but also capitalizes on the growing consumer demand for hemp-based nutritional and wellness products.
Strategic Positioning in a Competitive Landscape
SciSparc operates in a competitive and dynamic landscape where rigorous clinical research, robust intellectual property protection, and diversified revenue streams are critical. The company’s dual approach—pursuing breakthrough therapies through detailed clinical trials while also serving a broad consumer market with hemp-based products—allows it to mitigate risk and explore multiple avenues for value creation. By maintaining adherence to high standards of scientific inquiry and regulatory diligence, SciSparc reinforces its position as a trusted and innovative entity within the pharmaceutical and nutraceutical industries.
Expertise, Experience, and Trustworthiness
The expertise demonstrated by SciSparc’s team of senior executives and scientists adds a further layer of credibility to its endeavors. The company’s rigorous research protocols, combined with its strategic investments in cutting-edge technology and regulatory expertise, underscore its commitment to scientific excellence and long-term value creation. This methodical, research-intensive approach not only builds trust among stakeholders but also serves as a foundation for advancing next-generation therapies in areas that have long presented clinical challenges.
Conclusion
In summary, SciSparc Ltd exemplifies a forward-thinking pharmaceutical enterprise that effectively blends innovative drug development with consumer-oriented online sales. Its robust portfolio in cannabinoid-based immunotherapies, supported by extensive intellectual property and strategic clinical trials, positions it uniquely within a competitive market landscape. Whether addressing central nervous system disorders or fulfilling the growing consumer demand for hemp products, SciSparc’s dual business model represents a comprehensive and balanced approach to modern pharmaceutical innovation.
SciSparc Ltd. (NASDAQ: SPRC) has announced a collaboration with Polyrizon Ltd. to develop an innovative pain treatment using SciSparc's SCI-160 platform combined with Polyrizon's Trap and TargetTM technology. The goal is to create a proprietary intranasal formulation that maintains effective SCI-160 concentrations in the brain. SciSparc will pay up to $2,550,000 in development fees, plus royalties on product sales. Previous pre-clinical trials demonstrated SCI-160's efficacy and safety in pain management, with results comparable to high-dose morphine.
SciSparc Ltd. (NASDAQ: SPRC) announced a securities purchase agreement with a healthcare-focused investor, generating approximately $10 million in gross proceeds. The offering includes the issuance of 3,546,100 units, priced at $2.82 each, consisting of ordinary shares and warrants exercisable at $2.57. The transaction is set to close on or around June 1, 2022. Aegis Capital is the exclusive placement agent. The securities are being sold in a private placement and won't be registered under the Securities Act of 1933, requiring compliance with SEC regulations.
SciSparc Ltd. (NASDAQ: SPRC) has received Ethics Committee approvals for its Phase IIb clinical trial of SCI-110 targeting Tourette Syndrome (TS) at Hannover Medical School and Tel Aviv Sourasky Medical Center. This phase aims to assess the efficacy, safety, and tolerability of SCI-110 in adults aged 18-65, using the Yale Global Tic Severity Scale for measuring tic severity over 12 and 26 weeks. While the trial awaits health ministry approvals, the company continues to identify additional clinical sites to expedite patient enrollment. Positive results from earlier studies at Yale University encourage further development.
SciSparc Ltd. (NASDAQ: SPRC) announced positive results from a joint pre-clinical trial with Clearmind Medicine Inc. The trial evaluated the safety of SciSparc's CannAmide™ and Clearmind's psychedelic molecule MEAI for reducing alcohol consumption.
Findings showed high safety with no treatment-related changes across various organs. Significant reductions in alcohol intake were observed with MEAI at 40 mg/kg and lower doses combined with CannAmide™.
The company aims to further investigate the safety and efficacy of this novel treatment.
On May 10, 2022, SciSparc Ltd. (NASDAQ: SPRC) announced promising preclinical results from its collaboration with Clearmind Medicine Inc. The combination of SciSparc's CannAmide™ and Clearmind's MEAI has shown potential in significantly reducing alcohol consumption in treated animals. The collaboration led to a provisional patent application for this psychedelic combination therapy. Initial studies indicated a dose-dependent effect, with alcohol intake reduced by 40 mg/kg MEAI and dual treatment with 25 mg/kg CannAmide™. The company aims to strengthen its IP portfolio in the psychedelic sector.
SciSparc Ltd. (NASDAQ: SPRC), a clinical-stage pharmaceutical firm, filed its annual report on Form 20-F for the fiscal year 2021 with the SEC on May 2, 2022. Key achievements include the issuance of a U.S. patent for its technology targeting central nervous system disorders, recruitment of the first patient for a Phase IIa trial of SCI-110 in Alzheimer's, and progress in a Phase IIb trial for Tourette syndrome. The company also formed collaborations to develop psychedelic-based pharmaceuticals and entered a joint venture focused on drug discovery for cancer and infectious diseases.
SciSparc Ltd. (NASDAQ: SPRC), a clinical-stage pharmaceutical company, announced the completion of a joint venture agreement with MitoCareX Bio Ltd. to develop therapies targeting cancer and life-threatening conditions. SciSparc invested $700,000 of a planned $1.7 million, aiming for 50.01% ownership. MitoCareX will explore mitochondrial carriers, crucial for cell viability, to address various health issues. The development builds on successful trials in the UK. This strategic move reflects SciSparc's commitment to enhancing its portfolio in cannabinoid pharmaceuticals and addressing central nervous system disorders.
SciSparc Ltd. (NASDAQ: SPRC) has appointed Prof. Avi Schroeder to its Scientific Advisory Board to enhance the formulation development of its investigational pain treatment, SCI-160. The drug has shown positive results in pre-clinical trials for both acute and chronic pain. Prof. Schroeder brings extensive experience in targeted drug delivery and has made significant contributions to nanotechnology and medicine. The company plans to initiate the Pre-IND process later this year, aiming for an FDA IND Phase I study application.
SciSparc Ltd. (NASDAQ: SPRC) announced the formation of a joint venture, MitoCareX Bio Ltd., to focus on discovering and developing drugs for cancer and other serious conditions. The new Israeli-based company will explore the role of mitochondrial carriers in treating life-threatening diseases. SciSparc plans to invest up to $1.7 million over two years for a 50.01% stake, contingent on specific milestones. The initiative aims to leverage advanced drug discovery techniques and prior successful experiments in the UK, with expert Professor Ciro Leonardo Pierri advising the program.
SciSparc Ltd. (NASDAQ: SPRC), a clinical-stage pharmaceutical company, will present at the Aegis Capital Corp. Virtual Conference on February 24, 2022, at 8:30 a.m. EST. The conference runs from February 23-25, 2022. Interested parties can access the presentation by requesting it from Aegis during the conference dates. The slide deck will also be available on SciSparc's website. The company is focused on cannabinoid pharmaceuticals, with drug development programs targeting disorders such as Tourette syndrome, obstructive sleep apnea, and autism.
FAQ
What is the current stock price of Scisparc (SPRC)?
What is the market cap of Scisparc (SPRC)?
What is the primary focus of SciSparc Ltd?
How does SciSparc generate its revenue?
What types of disorders is SciSparc targeting?
How does SciSparc differentiate itself in the pharmaceutical industry?
What role do patents and proprietary technologies play at SciSparc?
How does SciSparc manage regulatory compliance?
What market segments does SciSparc serve?
How experienced is the management team at SciSparc?
